Oncopeptidomics: A useful approach for cancer diagnosis?

Clinical Chemistry

Volumn 53, Issue 6, 2007, Pages 1004-1006

  Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; PEPTIDE; PROTEIN;

ALGORITHM; ANALYTIC METHOD; BIOINFORMATICS; CANCER; CANCER DIAGNOSIS; EDITORIAL; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ONCOLOGY; ONCOPEPTIDOMICS; PEPTIDE ANALYSIS; PEPTIDOMICS; PROTEOMICS; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BLOOD PROTEINS; CARRIER PROTEINS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PEPTIDES; PROTEIN BINDING; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 34249907591     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.082552     Document Type: Editorial

References (26)

1. Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Petricoin III EF, Liotta LA, et al. "Top-down" discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples using a novel, high-throughput workflow. Clin Chem 2007;53:1067-74.
2. Petricoin III EF, Ardekani AM, Hitt BA, Levine PJ. Fusaro VA, Steinberg SM, et al. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
3. Check E. Proteomica and cancer: running before we can walk? Nature 2004;429:496-7.
4. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6.
5. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.
6. Diamandis EP, van der Merwe D-E. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancar Res 2005;11:963-5.
7. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-9.
8. Banks RE, Stanley AJ, Calms DA, Barrett JH, Clarke P, Thompson D, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51:1637-49.
9. Karsan A, Eigi, BJ, Ribotte S, Gelmon K, Switzer P, Hassell P, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 2005;51:1525-8.
10. Diamandls EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-8.
11. Petricoin E 3rd, Liotta LA. Counterpoint The vision of a new diagnostic paradigm. Clin Chem 2003;49:1276-8.
12. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003;425:905.
13. Schulte I, Tammen H, Selle H, Schulz-Knappe P. Peptides in body fluids and tissues as markers of disease. Expert Rev Mol Diagn 2005;5:145-57.
14. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361-72.
15. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, Golenko E, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005;51:1946-54.
16. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Areujo RP, Hood BL, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005;51:1933-45.
17. Villlanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84.
18. Diamandis EP, Kulasingam V, Sardana G. Letter to the Editor about differential exprotease activities confer tumor-specific serum peptidome. J Clin Invest 2006;464 http://www.jcl.org/cgl/eletters/116/1/271 (accessed December 2006).
19. Diamandis EP. Peptidomics for cancer diagnostics: present and future. J Proteome Res 2006;5:2079-82.
20. Koomen JM, LI D, Xiao L-C, Liu TC, Coombes KR, Abbruzzese J, et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 2005;4:972-81.
21. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-hight mass spectrometry for cancer diagnosis: Next steps. Cancer Res 2006;66:5540-1.
22. S. Carisson, Fibrinogen degradation products in serum from patients with cancer. Acta Chir Scand 1973;139:499-502.
23. Michiels S, Koscleiny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365:488-92.
24. Diamandis EP. Quality of the scientific literature: all that glitters is not gold. Clin Biochem 2006;39:1109-11.
25. Hortin GL, Jortani SA, Ritchie JC Jr, Valdes R Jr, Chan DW. Proteomics: a new diagnostic frontier. Clin Chem 2006;52:1218-22.
26. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006;52:1223-37.